miR-222 induces apoptosis in human intervertebral disc nucleus pulposus cells by targeting Bcl-2

WEI WANG¹, JIAN WANG², JIAYI ZHANG², WEI TAQ³ and ZHENXING ZHANG⁴

Departments of ¹Rehabilitation, ²Orthopedics, ³General Surgery and ⁴Neurosurgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, P.R. China

Received March 11, 2019; Accepted August 6, 2019

DOI: 10.3892/mmr.2019.10732

Abstract. Intervertebral disc degeneration (IDD) is characterized by abnormal induction of apoptosis in intervertebral disc nucleus pulposus (NP) cells. Previous studies indicated that miR-222 was upregulated in patients with rheumatoid arthritis. However, the effects of miR-222 in IDD remain unclear. The present study aimed to demonstrate the role of miR-222 in NP cells. The levels of miR-222 in patients with IDD were measured by reverse transcription-quantitative PCR. Cell Counting Kit-8 and western blotting assays were used to detect cell proliferation and apoptosis-associated protein levels, respectively. In addition, luciferase reporter assays were performed to validate the predicted target genes of miR-222. miR-222 was significantly upregulated in patients with IDD. Overexpression of miR-222 inhibited cell proliferation and induced cell apoptosis. Moreover, overexpression of miR-222 resulted in an upregulation in the levels of Bax and cleaved caspase 3, and a downregulation in the levels of Bcl-2 in NP cells. The luciferase reporter assays demonstrated that Bcl-2 is a target of miR-222. Furthermore, overexpression of miR-222 increased the levels of cytochrome c, apoptotic protease activating factor-1 and cleaved caspase 9 in NP cells. Conversely, downregulation of miR-222 could promote the proliferation of NP cells. The present data demonstrated that miR-222 induced apoptosis in NP cells by directly targeting Bcl-2. Therefore, miR-222 may act as a potential therapeutic target for the treatment of IDD.

Introduction

Low back pain is a common and chronic disease (1). In total, >80% of adults will suffer from back pain at a certain stage in their lives (2). Intervertebral disc degeneration (IDD) is a common cause of lower back pain, and 20-33% of the patients with this disorder will not be able to work (3,4). Moreover, IDD is also a prevalent musculoskeletal disorder, which may serve as a social and economic burden worldwide (5). At present, endoscopic lumbar discectomy is the common treatment method for IDD. However, this method may lead to recurrence of the disease following surgery (6,7). At present, no effective preventative strategy and therapeutic method has been reported for treating IDD, due to the diversity and the unclear cause of low back pain. Therefore, it is important to identify the mechanism responsible for the development of IDD.

MicroRNAs (miRNAs) are endogenous short non-coding RNAs, which consist of ~20 nucleotides (8). miRNAs play vital roles in the regulation of gene expression by controlling related physiological processes (9). Previous studies reported that miRNAs are involved in cell growth, proliferation and cell death in different diseases (10-12). It has been shown that some miRNAs exert an important role in the development of IDD, such as miR-194, miR-3150a and miR-125b-1 (13-15).

miR-222 acts as a tumor promoter in different cancer types, such as pancreatic and breast cancer (16,17). miR-222 regulates the inflammatory response of macrophages in bacterial pneumonia (18). In addition, miR-222 regulates marrow niche-supported tumor cells, which promote survival of residual cells (19). A previous study indicated that the levels of miR-222 were upregulated in patients with rheumatoid arthritis (20). However, although various previous studies have been conducted on the biological functions of miR-222, the role of miR-222 in IDD remains unclear. In the present study, evidence is presented supporting the role of miR-222 in inducing the apoptosis of NP cells via Bcl-2 regulation.

Materials and methods

Patient samples. A total of 20 lumbar nucleus pulposus specimens were collected from patients with IDD between April 2017 and May 2018; the patients included 12 females and 8 males (ranging 43-65 years old) in the First Affiliated Hospital of the Jinzhou Medical University. Patients with diabetes mellitus, spondylolisthesis, serious systemic disease, ankylosing spondylitis, trauma history of the spine, or back surgery were excluded. In total, 20 matched healthy controls, recruited from public schools, were included in the
present study. The present study was approved by the Ethics Committee of the First Affiliated Hospital of the Jinzhou Medical University, and informed consent was obtained from each participant prior to enrollment.

**Cell culture and transfection.** Human intervertebral disc nucleus pulposus (NP) cells were obtained from the Tongpai Biological Technology Co., Ltd. (http://www.shtbio.com/tongpai-Products-3469763/). These cells are primary cells. NP cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 µg/ml streptomycin and 100 U/ml penicillin. The cells were incubated at 37°C in a humidified atmosphere with 5% CO₂.

The 10 nM miR-222 mimics, 10 nM miR-222 inhibitor and 10 nM mimics negative control (NC) were obtained from Shanghai GenePharma Co., Ltd. Briefly, the cells (2x10⁶ cells/well) were plated in 6-well plates overnight. The sequence for miR-222 mimics was: 5'-AGCUACAUCUGG CUACUGGGU-3'. The sequence for miR-222 inhibitor was: 5'-ACCCAGUAGCCAGAGCU-3'. The sequence for NC was: 5'-UUUGUACUACACAAAGAUCG-3'. Subsequently, miR-222 mimics or miR-222 inhibitor were transfected into the cells using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The transfection efficiency of miR-222 mimics in NP cells was assessed using reverse transcription-quantitative PCR (RT-qPCR) following 72 h of growth after cell transfection.

**RT-qPCR.** Total RNA extraction from the lumbar nucleus pulposus specimens and cells was performed using an RNA extraction kit (Total RNA Purification kit; Sigma Aldrich; Merck KGaA). Total RNA was reverse transcribed into cDNA using the TaqMan® MicroRNA RT kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The RT reaction conditions were as follows: 37°C for 60 min, followed by 85°C for 5 min and 4°C. The cDNA samples were subjected to real-time PCR using a SYBR Green One-Step RT-qPCR kit (Thermo Fisher Scientific, Inc.) on an ABI 7900HT instrument (ABI; Thermo Fisher Scientific, Inc.). The qRCC reaction conditions were as follows: 95°C for 3 min, followed by 40 cycles at 95°C for 10 sec, 58°C for 30 sec and 72°C for 30 sec. The primer sequences for miR-222 were as follows: Forward primer: 5'-AGCUACAUCUGGCUACUGGGU-3' and reverse primer: 5'-CCAGUAGCCAGAGCUACGUU-3'. The primer sequences for U6 were as follows: Forward primer: 5'-CTCCGCTTGGCAAGACCAT-3' and reverse primer: 5'-AACGCTTCAGGAATTTGGC-3'. All samples were tested in triplicate. The relative expression was measured using the 2^ΔΔCq method (21). Gene expression results were normalized by the internal control U6.

**Cell Counting Kit-8 assay.** Cell viability was assessed using CCK-8 (Beyotime Institute of Biotechnology). NP cells (2x10⁶ cells/well) were seeded into 96-well plates overnight. Subsequently, miR-222 mimics or miR-222 inhibitor were added into each well for 0, 24, 48 and 72 h. A total of 10 µl CCK-8 reagent was added into each well for 2 h. The absorbance of each well was determined at 450 nm with a microplate reader (Molecular Devices, LLC).

**Immunofluorescence assay.** NP cells (1x10⁵ cells/well) were plated into 24-well plates overnight. Subsequently, miR-222 mimics, miR-222 inhibitor or mimics control were added into each well. The cells were fixed in 4% paraformaldehyde for 20 min at room temperature, and in ice-cold 100% methanol for an additional 20 min at -20°C. After 30 min of blocking with 3% BSA in TBST at room temperature, the cells were incubated with the following antibodies: Anti-proliferation marker protein Ki-67 (Ki67; Abcam; cat. no. ab15580; 1:1,000), anti-Bcl-2 (Abcam; cat. no. ab32124; 1:1,000) and DAPI antibody (cat. no. ab104139; 1:1,000) at 4°C overnight. The following morning, horseradish peroxidase-conjugated Goat anti-rabbit IgG secondary antibodies (Abcam; cat. no. ab150081; 1:5,000) were added for 1 h to the cells at room temperature. The cells were observed with a Leica confocal microscopy (Leica; magnification, x400) and the images were analyzed using the Leica LAS-X software.

**Flow cytometry analysis of cell apoptosis.** NP cells (5x10⁶ cells/well) were seeded into 96-well plates overnight. miR-222 mimics, or mimics control were added into each well for 72 h. The cells were collected, washed 3 times with cold PBS and resuspended in 1X binding buffer. The cells were stained with dual-staining Annexin V-FITC-propidium iodide (PI; Thermo Fisher Scientific, Inc.) for 20 min at room temperature according to the manufacturer's protocol. The results were analyzed using a FACS Calibur flow cytometer (BD Biosciences) on a BD FACSCalibur system (FACScan, BD Biosciences).

**Western blot analysis.** The proteins were extracted from the cells using RIPA lysis buffer (Thermo Fisher Scientific, Inc.) and their concentration levels were quantified using a bicinchoninic acid protein assay kit (Bioytime Institute of Biotechnology). The proteins (40 µg per lane) were separated by SDS-PAGE on 10% gels, and were transferred onto 0.45 µm PVDF membranes (Thermo Fisher Scientific, Inc.). Following blocking with 5% non-fat milk at room temperature for 1 h, the membranes were incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: Anti-Bax (Abcam; cat. no. ab32503; 1:1,000), anti-Bcl-2 (Abcam; cat. no. ab32124; 1:1,000), anti-cleaved caspase 3 (Abcam; cat. no. ab2302; 1:1,000), anti-cytochrome c (Cyto C; Abcam; cat. no. ab13575; 1:1,000), anti-apoptotic protease activating factor-1 (Apaf 1; Abcam; cat. no. ab2001; 1:1,000), anti-cleaved caspase 9 (Abcam; cat. no. ab2324; 1:1,000) and anti-β-actin (Abcam; cat. no. ab8227; 1:1,000).

Subsequently, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (Abcam; cat. no. ab150077; 1:200) for 1 h at room temperature. Finally, an image of the protein band was detected using ECL reagent (Santa Cruz Biotechnology, Inc.). Image-Pro Plus software (version 7, Media Cybernetics, Inc.) was used for the targets that were normalized to β-actin.

**Luciferase reporter assay.** The potential target genes of miR-222 were predicted using miRanda (http://www.microrna.org), miRDB (http://www.mirdb.org/) and TargetScan (http://www.targetscan.org/). The target gene sequence and the mutation gene sequence were synthesized by Shanghai
GenePharma Co., Ltd. The 3'-untranslated region (3'-UTR) of Bcl-2 was amplified from genomic DNA and inserted into the psiCHECK-2 vector (Promega Corporation) using the XhoI and NotI sites. NP cells were co-transfected with psiCHECK2-Bcl-2-wild-type + miR-222 mimics, and psiCHECK2-Bcl-2-mutated type + miR-222 mimics using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.). The cells were incubated in 5% CO₂ at 37˚C for 48 h. The dual luciferase reporter assay system (Promega Corporation) was used to measure luciferase activity. The firefly luciferase activity was normalized, according to Renilla luciferase activity.

Statistical analysis. Each sample was assessed for at least three independent determinations. Data are presented as mean ± standard error. Graphs were generated using GraphPad Prism software (version 7.0, GraphPad Software, Inc.). The comparison between the two groups was analyzed by the Student's t-test. The comparisons among multiple groups were performed with one-way ANOVA followed by the Dunnett's test. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-222 expression levels are increased in IDD tissues and NP cells. To investigate the role of miR-222 in the development of IDD, RT-qPCR was used to detect the levels of miR-222 in IDD and normal disc tissues. A total of 20 human IDD tissues were used with corresponding control samples. The mean levels of miR-222 were significantly increased compared with the normal group (Fig. 1A). In addition, RT-qPCR was used to detect miR-222 levels in NP cells, following transfection with miR-222 mimics for 0, 24, 48 and 72 h. The expression levels of miR-222 in NP cells were significantly increased following transfection with miR-222 mimics for 48 and 72 h (Fig. 1B). miR-222 mimics were further used in the present study to successfully increase the levels of miR-222 in NP cells. The levels of miR-222 were significantly upregulated in NP cells following transfection with miR-222 mimics for 72 h (Fig. 1C). These results indicated that the levels of miR-222 were increased in IDD tissues and NP cells.

miR-222 overexpression inhibits proliferation of NP cells. To study the effects of miR-222 on NP cells, a CCK-8 assay was used to detect cell viability. Overexpression of miR-222 inhibited cell proliferation (Fig. 2A). Similarly, the results of the immunofluorescence assay demonstrated that the overexpression of miR-222 significantly decreased the number of Ki67 positive cells (Fig. 2B and C). The data suggested that miR-222 overexpression inhibited proliferation of NP cells.

miR-222 overexpression induces apoptosis of NP cells. To further determine whether miR-222 was responsible for the induction of apoptosis in NP cells, flow cytometry was employed to analyze the extent of apoptosis. The cell apoptotic rate was markedly increased in the miR-222 mimics group...
WA NG et al: miR-222 INDUCES APOPTOSIS IN IDD CELLS

compared with the NC group (Fig. 3A and B). In addition, the expression levels of the apoptotic proteins Bax and cleaved caspase 3 were significantly increased, while the level of Bcl-2 was reduced in the miR-222 mimics group (Fig. 3C-F). These data suggest that miR-222 overexpression induced apoptosis of NP cells.
Figure 4. Bcl-2 is the target gene of miR-222. (A) Sequence alignment of human miR-222 with Bcl-2. (B) NP cells were transfected with NC and miR-222 mimics, and the relative fluorescence expression levels were observed by Bcl-2 detection and DAPI staining (magnification, ×400). (C) Luciferase reporter assays were used to detect the luciferase activity. The cells in the WT group were treated with psiCHECK2-Bcl-2-WT+miR-NC and psiCHECK2-Bcl-2-WT+miR-222 mimics separately. The cells in the MT group were treated with psiCHECK2-Bcl-2-MT+miR-NC and psiCHECK2-Bcl-2-MT+miR-222 mimics separately. Both firefly and Renilla luciferase activities were measured in the same sample. The firefly luciferase activity was normalized, according to Renilla luciferase activity. (D) Protein expression levels of Cyto C, Apaf 1 and cleaved caspase 9 detected in the intervertebral disc NP cells following transfection with NC and miR-222 mimics. Relative expression levels of (E) Cyto C, (F) Apaf 1 and (G) cleaved caspase 9 were quantified by normalizing them to the levels of β-actin. *P<0.01 vs. the NC group. miR, microRNA; NP, nucleus pulposus; NC, negative control; WT, wild-type; MT, mutant type; Cyto C, cytochrome C; Apaf 1, apoptotic protease activating factor-1.
**Bcl-2 is a target gene of miR-222.** As predicted by miRanda, miRDB and TargetScan, there was complementary binding between miR-222 and Bcl-2. The miR-222 sequence exhibited a binding site for the 3'-UTR of wild-type Bcl-2 (Fig. 4A). To further confirm the functional interaction between miR-222 and Bcl-2, immunofluorescence and luciferase reporter assays were used to verify the binding of miR-222 to its target. The expression levels of Bcl-2 were markedly decreased in the miR-222 mimics group compared with the NC group (Fig. 4B). In addition, overexpression of miR-222 markedly decreased the luciferase activity of the reporter gene with regard to the wild-type genotype, whereas the transfection of the cells with miR-222 mimics exhibited no significant effect on the mutant genotype, indicating that miR-222 directly targeted the 3'-UTR of Bcl-2 (Fig. 4C). In addition, the expression levels of the mitochondrial apoptotic pathway-associated proteins, Cyto C, Apaf 1 and cleaved caspase 9, were significantly increased in the miR-222 mimics group compared with the NC group. These data suggested that miR-222 induced cell apoptosis by targeting Bcl-2 in NP cells.

**Downregulation of miR-222 promotes proliferation of NP cells.** The data derived from the previous experiments demonstrated that miR-222 overexpression could inhibit proliferation of NP cells. To further investigate the biological roles of miR-222 on NP cells, the cells were transfected with an miR-222 inhibitor. The levels of miR-222 were significantly downregulated in NP cells following transfection of the miR-222 inhibitor (Fig. 5A). In addition, downregulation of miR-222 promoted cell proliferation (Fig. 5B). Similarly, the results of the immunofluorescence assay suggested that downregulation of miR-222 increased Ki67 positive cells compared with the NC group (Fig. 5C and D). The present data suggested that downregulation of miR-222 promoted proliferation of NP cells.

**Discussion**

Despite the recent advances of experimental medicine, the therapeutic applications for IDD are still limited. Therefore, new therapeutic strategies are required for the treatment of IDD. In the present study, it was demonstrated that miR-222 levels were upregulated in IDD tissues. In addition, upregulation of miR-222 could inhibit proliferation and induce apoptosis of NP cells. Abo et al (20) suggested that the expression levels of miR-222 were increased in patients with rheumatoid arthritis. In addition, Nie and Tan (22) indicated that miR-222 was upregulated in patients with uterine cancer. Therefore, these
results indicated that miR-222 may play a role in inhibiting cell proliferation.

Apoptosis is a physiological process, which can remove harmful or seriously injured cells and organelles. A previous study indicated that the inhibition of apoptosis in NP cells could retard disc degeneration. A decrease in the number of NP cells was associated with the development of IDD, and inhibition of cell apoptosis was used as a strategy to reverse IDD. In the present study, the data demonstrated that miR-222 induced apoptosis in NP cells by reducing the levels of Bcl-2, and increasing the levels of Bax and cleaved caspase 3. Zhang et al further demonstrated that miR-222 induced apoptosis in glioma cells by decreasing the levels of Bcl-2 and increasing the levels of Bax. These data suggested that miR-222 could induce apoptosis in NP cells.

In the present study, a novel mechanism of the miR-222-associated therapeutic action for the treatment of IDD was proposed. The present results indicated that Bcl-2 is a target gene of miR-222 in NP cells, as determined by a luciferase reporter assay. Bcl-2 is an anti-apoptotic protein, which belongs to the Bcl-2 family of proteins, and is considered a classical biomarker of the mitochondrial pathway of apoptosis. In apoptosis, external stimuli, such as cytotoxic agents, could result in mitochondrial dysfunction, and then result in the release of pro-apoptotic protein Cyt c and activation of caspases to induce apoptosis. Previous studies demonstrated that the dissociation of the Bcl-2/Bax complex can lead to the release of Cyto C (29,30). The proteins Cyto C, Apaf-1 and caspase-9 form the apoptosome, which increases the levels of cleaved caspase-9 and leads to induction of apoptosis (30). In the present study, it was demonstrated that overexpression of miR-222 increased the levels of Cyto C, Apaf 1 and caspase 9 by targeting Bcl-2. The present data suggested that miR-222 induced apoptosis of NP cells via the mitochondrial-dependent apoptotic pathway. A decrease in the levels of Bcl-2 and a concomitant increase in the levels of cleaved caspase 3, cleaved caspase 9 and Bax were detected in NP cells, which was consistent with the data reported in a previous study (31). In addition, it is important to note that downregulation of miR-222 promoted proliferation of NP cells. The present findings demonstrated that overexpression of miR-222 induced apoptosis of NP cells via the mitochondrial-mediated apoptotic pathway. However, further studies are needed to investigate the role of miR-222 in animal model of intervertebral disc nucleus pulposus.

In conclusion, the present study demonstrated that miR-222 induces apoptosis in human NP cells by directly targeting Bcl-2. In addition, miR-222 may play a role in inhibiting cell proliferation and inducing cell apoptosis in human NP cells. Therefore, miR-222 may act as a potential therapeutic target for the treatment of IDD.

Acknowledgements

Not applicable.

Funding

The present study was funded by The Department of Science and Technology of the Liaoning Preparation of Animal Models and Animal Experimental Research for Major Diseases (grant no. 2012408002).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

WW and JW analyzed and interpreted the patient data, and were major contributors in the development of the first draft of the present manuscript. JZ and WT participated in the experimental design, tissue collection and experimental execution. ZZ participated in the experimental design and experimental execution, and reviewed and approved the final draft of the manuscript prior to submission.

Ethics approval and consent to participate

Ethics approval for the present study was provided by The First Affiliated Hospital of The Jinhzhou Medical University Ethics Committee, and informed consent was obtained from each participant prior to enrollment.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.